NCT00245466View on ClinicalTrials.gov

Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Given as a subcutaneous injection once every 4 weeks.

DRUG

Degarelix

Given as a subcutaneous injection once every 4 weeks.

DRUG

Degarelix

Given as a subcutaneous injection once every 4 weeks.

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY